Membrane-Bound Enzyme Linked to Plaque Formation in Mouse Atherosclerosis Model
By LabMedica International staff writers Posted on 21 Jul 2015 |
Image: Results presented in this study suggest that the enzyme CD39 can suppress the plaque buildup that may trigger heart attack or stroke (Photo courtesy of the University of Michigan).
Cardiac disease researchers working with a mouse model of atherosclerosis have found that that a specific membrane bound enzyme has the potential to inhibit build-up of plaque and reduce risk of heart attack or stroke.
Investigators at the University of Michigan (Ann Arbor, USA) worked with the apolipoprotein E-deficient (ApoE-deficient) mouse model of atherosclerosis to examine the role of the enzyme CD39 (ectonucleotide tri(di)phosphohydrolase-1 or ENTPD1) in the process of plaque formation. This enzyme metabolizes locally released, intravascular ATP and ADP, thereby eliminating these pro-thrombotic and pro-inflammatory signaling molecules.
The investigators reported in the June 29, 2015, online edition of the Journal of Clinical Investigation that when animals fed a high-fat diet were compared, it was seen that ApoE-deficient mice that also lacked CD39 had a plaque burden that was markedly increased along with circulating markers of platelet activation. CD39 was prominently expressed in stable blood flow regions and was diminished in areas subjected to disturbed flow. Thus, CD39 activation followed the pattern of plaque formation.
In mice, disturbed blood flow as the result of partial carotid artery ligation rapidly suppressed endothelial CD39 expression. Moreover, unidirectional laminar shear stress induced protective CD39 expression in human endothelial cells.
“Better lifestyles and improved treatments have slowed the rates of death from atherosclerosis, but if CD39 proves to be as critical a factor in humans as in mice, it would be a major step forward in understanding heart disease,” said senior author Dr. David Pinsky, professor of cardiology at the University of Michigan.
Related Links:
University of Michigan
Investigators at the University of Michigan (Ann Arbor, USA) worked with the apolipoprotein E-deficient (ApoE-deficient) mouse model of atherosclerosis to examine the role of the enzyme CD39 (ectonucleotide tri(di)phosphohydrolase-1 or ENTPD1) in the process of plaque formation. This enzyme metabolizes locally released, intravascular ATP and ADP, thereby eliminating these pro-thrombotic and pro-inflammatory signaling molecules.
The investigators reported in the June 29, 2015, online edition of the Journal of Clinical Investigation that when animals fed a high-fat diet were compared, it was seen that ApoE-deficient mice that also lacked CD39 had a plaque burden that was markedly increased along with circulating markers of platelet activation. CD39 was prominently expressed in stable blood flow regions and was diminished in areas subjected to disturbed flow. Thus, CD39 activation followed the pattern of plaque formation.
In mice, disturbed blood flow as the result of partial carotid artery ligation rapidly suppressed endothelial CD39 expression. Moreover, unidirectional laminar shear stress induced protective CD39 expression in human endothelial cells.
“Better lifestyles and improved treatments have slowed the rates of death from atherosclerosis, but if CD39 proves to be as critical a factor in humans as in mice, it would be a major step forward in understanding heart disease,” said senior author Dr. David Pinsky, professor of cardiology at the University of Michigan.
Related Links:
University of Michigan
Latest BioResearch News
- Genome Analysis Predicts Likelihood of Neurodisability in Oxygen-Deprived Newborns
- Gene Panel Predicts Disease Progession for Patients with B-cell Lymphoma
- New Method Simplifies Preparation of Tumor Genomic DNA Libraries
- New Tool Developed for Diagnosis of Chronic HBV Infection
- Panel of Genetic Loci Accurately Predicts Risk of Developing Gout
- Disrupted TGFB Signaling Linked to Increased Cancer-Related Bacteria
- Gene Fusion Protein Proposed as Prostate Cancer Biomarker
- NIV Test to Diagnose and Monitor Vascular Complications in Diabetes
- Semen Exosome MicroRNA Proves Biomarker for Prostate Cancer
- Genetic Loci Link Plasma Lipid Levels to CVD Risk
- Newly Identified Gene Network Aids in Early Diagnosis of Autism Spectrum Disorder
- Link Confirmed between Living in Poverty and Developing Diseases
- Genomic Study Identifies Kidney Disease Loci in Type I Diabetes Patients
- Liquid Biopsy More Effective for Analyzing Tumor Drug Resistance Mutations
- New Liquid Biopsy Assay Reveals Host-Pathogen Interactions
- Method Developed for Enriching Trophoblast Population in Samples